NEJM: Peer-Reviewed Study Finds CBD is Real Medicine
On Wednesday, the New England Journal of Medicine (NEJM) published a report that demonstrates Cannabidiol (CBD) – the therapeutic non-psychoactive cannabinoid found in marijuana – reduces seizures in children suffering from drug-resistant forms of epilepsy.
Validated by the New England Journal of Medicine, GW Pharmaceuticals phase 3 CDB trail was found to help some patients more than others.
For their double-blind peer-reviewed study, scientists from the NEJM “randomly assigned 120 children and young adults with the Dravet syndrome and drug-resistant seizures to receive either cannabidiol oral solution at a dose of 20 mg per kilogram of body weight per day or placebo, in addition to standard antiepileptic treatment.”
Dravet syndrome is considered a rare genetic form of epilepsy, seizures typically begin in the first year of life. And, as it currently stands, there are no pharmaceutical options specifically approved for the treatment of Dravet syndrome.
Science, Cannabinoids, and Epilepsy — At Last, Real Data
For their 14-week trial, the NEJM found the median “frequency of convulsive seizures per month decreased” for those in the cannabidiol group from 12.4 to 5.9; those suffering from seizures in the placebo group remained relatively stagnant, decreasing from 14.9 to 14.1.